# China NMPA Product Recall - Avaira Soft Hydrophilic Contact Lens

Source: https://www.globalkeysolutions.net/records/china_product_recall/coopervision-manufacturing-ltd/6b27d61f-bab2-428b-8591-7aeaee2416c7/
Source feed: China

> China NMPA product recall for Avaira Soft Hydrophilic Contact Lens by CooperVision Manufacturing Ltd. published November 25, 2011. Recall level: Level 1 Recall. CooperVision Manufacturing Ltd., in conjunction with its Chinese affiliate, CooperVision Optical Pro

---

## Details

- Record Type: CHINA_PRODUCT_RECALL
- Title: CooperVision Manufacturing Ltd. is recalling Avaira soft hydrophilic contact lenses.
- Company Name: CooperVision Manufacturing Ltd.
- Publication Date: 2011-11-25
- Product Name: Avaira Soft Hydrophilic Contact Lens
- Recall Level: Level 1 Recall
- Recall Reason: Coopervision has discovered residue (silicone oil) in certain batches of lenses that does not meet our latest quality requirements. Residue on Avaira soft hydrophilic contact lenses may cause blurred vision, eye discomfort, eye pain requiring treatment, or eye damage.
- Discovering Company: Cooper Optical Products Trading (Shanghai) Co., Ltd.
- Manufacturing Company: CooperVision Manufacturing Ltd.
- Summary: CooperVision Manufacturing Ltd., in conjunction with its Chinese affiliate, CooperVision Optical Products Trading (Shanghai) Co., Ltd., initiated a Class I voluntary recall of certain batches of Avaira soft hydrophilic contact lenses. This action was officially reported by the National Medical Products Administration (NMPA) on November 25, 2011. The primary issue identified was the presence of silicone oil residue in specific lens batches, which did not meet the company's stringent quality specifications. This quality lapse posed potential health risks to users, including blurred vision, eye discomfort, pain requiring treatment, and even eye damage. The NMPA requested all provincial, autonomous region, and municipal food and drug administrations to enhance supervision of such products, underscoring the seriousness of the recall under Chinese medical device regulations. In response to the identified defect, CooperVision implemented a comprehensive set of corrective actions. These included a thorough quality control analysis to pinpoint and rectify the production error within their quality system. They also promptly identified, isolated, and halted the further distribution of all affected product batches, impacting 6,360 units globally, with 5,756 units sold in China. Furthermore, the company contacted all distributors to ensure the recall process was initiated effectively and established a dedicated customer hotline to address inquiries, demonstrating a commitment to patient safety and regulatory compliance.

Company: https://www.globalkeysolutions.net/companies/coopervision-manufacturing-ltd/d7327b5a-b614-4b1a-91b1-3b04371c966b/